Skip to main content

Articles

Page 27 of 32

  1. We present a new method to analyze cancer of unknown primary origin (CUP) samples. Our method achieves good results with classification accuracy (88% leave-one-out cross validation for primary tumors from 56 c...

    Authors: Kalle A Ojala, Sami K Kilpinen and Olli P Kallioniemi
    Citation: Genome Medicine 2011 3:63
  2. Pharmacogenetic testing holds major promise in allowing physicians to tailor therapy to patients based on genotype. However, there is little data on the impact of pharmacogenetic test results on patient and cl...

    Authors: Wendy Lorizio, Hope Rugo, Mary S Beattie, Simone Tchu, Teri Melese, Michelle Melisko, Alan HB Wu, H Jeffrey Lawrence, Michele Nikoloff and Elad Ziv
    Citation: Genome Medicine 2011 3:64
  3. Stem cells hold great promise for pancreatic beta cell replacement therapy for diabetes. In type 1 diabetes, beta cells are mostly destroyed, and in type 2 diabetes beta cell numbers are reduced by 40% to 60%....

    Authors: Gordon C Weir, Claudia Cavelti-Weder and Susan Bonner-Weir
    Citation: Genome Medicine 2011 3:61
  4. The hepatitis C virus (HCV) infects nearly 3% of the World's population, causing severe liver disease in many. Standard of care therapy is currently pegylated interferon alpha and ribavirin (PegIFN/R), which i...

    Authors: Katherine R Smith, Vijayaprakash Suppiah, Kate O'Connor, Thomas Berg, Martin Weltman, Maria Lorena Abate, Ulrich Spengler, Margaret Bassendine, Gail Matthews, William L Irving, Elizabeth Powell, Stephen Riordan, Golo Ahlenstiel, Graeme J Stewart, Melanie Bahlo, Jacob George…
    Citation: Genome Medicine 2011 3:57
  5. Hypoxia is a feature of most solid tumors and is associated with poor prognosis in several cancer types, including breast cancer. The master regulator of the hypoxic response is the Hypoxia-inducible factor 1α...

    Authors: Elena Favaro, Simon Lord, Adrian L Harris and Francesca M Buffa
    Citation: Genome Medicine 2011 3:55
  6. Q fever is a worldwide zoonosis caused by Coxiella burnetii. The disease most frequently manifests clinically as a self-limited febrile illness, as pneumonia (acute Q fever) or as a chronic illness that presents ...

    Authors: Malgorzata Kowalczewska, Zuzana Sekeyová and Didier Raoult
    Citation: Genome Medicine 2011 3:50
  7. Genetic risk models could potentially be useful in identifying high-risk groups for the prevention of complex diseases. We investigated the performance of this risk stratification strategy by examining epidemi...

    Authors: Raluca Mihaescu, Ramal Moonesinghe, Muin J Khoury and A Cecile JW Janssens
    Citation: Genome Medicine 2011 3:51
  8. Innovative 'systems' approaches to biomedical research offer substantial promise for advancing knowledge and improving health care, as outlined by Bousquet et al. in this issue. However, they are unlikely to impr...

    Authors: Wylie Burke and Susan Brown Trinidad
    Citation: Genome Medicine 2011 3:47
  9. Data sharing is increasingly regarded as an ethical and scientific imperative that advances knowledge and thereby respects the contributions of the participants. Because of this and the ever-increasing amount ...

    Authors: Bartha Maria Knoppers, Jennifer R Harris, Anne Marie Tassé, Isabelle Budin-Ljøsne, Jane Kaye, Mylène Deschênes and Ma'n H Zawati
    Citation: Genome Medicine 2011 3:46
  10. We propose an innovative, integrated, cost-effective health system to combat major non-communicable diseases (NCDs), including cardiovascular, chronic respiratory, metabolic, rheumatologic and neurologic disor...

    Authors: Jean Bousquet, Josep M Anto, Peter J Sterk, Ian M Adcock, Kian Fan Chung, Josep Roca, Alvar Agusti, Chris Brightling, Anne Cambon-Thomsen, Alfredo Cesario, Sonia Abdelhak, Stylianos E Antonarakis, Antoine Avignon, Andrea Ballabio, Eugenio Baraldi, Alexander Baranov…
    Citation: Genome Medicine 2011 3:43
  11. Genome-wide association studies have identified several genomic regions that are associated with breast cancer risk, but these provide an explanation for only a small fraction of familial breast cancer aggrega...

    Authors: Ying Huang, Dennis G Ballinger, James Y Dai, Ulrike Peters, David A Hinds, David R Cox, Erica Beilharz, Rowan T Chlebowski, Jacques E Rossouw, Anne McTiernan, Thomas Rohan and Ross L Prentice
    Citation: Genome Medicine 2011 3:42

    The Erratum to this article has been published in Genome Medicine 2012 4:19

  12. Embryonic stem cell specific microRNAs (miRNAs) have previously been shown to enhance the efficiency of transcription-factor-based reprogramming. However, whether reprogramming could be achieved entirely by mi...

    Authors: Tamer T Onder and George Q Daley
    Citation: Genome Medicine 2011 3:40
  13. Achieving 'personalized medicine' requires enrolling representative cohorts into genetic studies, but patient self-selection may introduce bias. We sought to identify characteristics associated with genetic co...

    Authors: David E Lanfear, Philip G Jones, Sharon Cresci, Fengming Tang, Saif S Rathore and John A Spertus
    Citation: Genome Medicine 2011 3:39
  14. Human pluripotent cells such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) and their in vitro differentiation models hold great promise for regenerative medicine as they provide...

    Authors: Alvaro Rada-Iglesias and Joanna Wysocka
    Citation: Genome Medicine 2011 3:36
  15. In order to identify novel loci associated with Alzheimer's disease (AD), we conducted a genome-wide association study (GWAS) in the Spanish population.

    Authors: Carmen Antúnez, Mercè Boada, Antonio González-Pérez, Javier Gayán, Reposo Ramírez-Lorca, Juan Marín, Isabel Hernández, Concha Moreno-Rey, Francisco Jesús Morón, Jesús López-Arrieta, Ana Mauleón, Maitée Rosende-Roca, Fuensanta Noguera-Perea, Agustina Legaz-García, Laura Vivancos-Moreau, Juan Velasco…
    Citation: Genome Medicine 2011 3:33
  16. Systemic lupus erythematosus is a systemic, heterogeneous autoimmune disease. Understanding of its molecular complexity is incomplete and there is a need to identify new therapeutic targets and to optimize cri...

    Authors: Cornelis L Verweij and Saskia Vosslamber
    Citation: Genome Medicine 2011 3:30
  17. A report on the 'Genomic Disorders 2011 - The Genomics of Rare Diseases' meeting, Wellcome Trust Sanger Institute, Hinxton, UK, 23-26 March 2011

    Authors: Kathleen H Burns and Aravinda Chakravarti
    Citation: Genome Medicine 2011 3:29
  18. The anticonvulsant carbamazepine has a high incidence of cutaneous adverse drug reactions. A recent prospective clinical trial in Taiwan has indicated that HLA-B*1502 screening will reduce the incidence of life-t...

    Authors: Taisei Mushiroda and Yusuke Nakamura
    Citation: Genome Medicine 2011 3:28
  19. Colorectal cancer (CRC) is a heterogeneous disease that, on the molecular level, can be characterized by inherent genomic instabilities; chromosome instability and microsatellite instability. In the present st...

    Authors: Anita Sveen, Trude H Ågesen, Arild Nesbakken, Torleiv O Rognum, Ragnhild A Lothe and Rolf I Skotheim
    Citation: Genome Medicine 2011 3:32
  20. The study of rare variants holds the promise of accounting for some of the missing heritability in complex traits. Next-generation sequencing technologies enable probing of variation across the full spectrum o...

    Authors: Jennifer Asimit and Eleftheria Zeggini
    Citation: Genome Medicine 2011 3:24
  21. Persons with schizophrenia and other psychotic disorders have a high prevalence of obesity, impaired glucose tolerance, and lipid abnormalities, particularly hypertriglyceridemia and low high-density lipoprote...

    Authors: Matej Orešič, Jing Tang, Tuulikki Seppänen-Laakso, Ismo Mattila, Suoma E Saarni, Samuli I Saarni, Jouko Lönnqvist, Marko Sysi-Aho, Tuulia Hyötyläinen, Jonna Perälä and Jaana Suvisaari
    Citation: Genome Medicine 2011 3:19
  • Editorial Board
  • Editorial Team
  • Call for EBMs
  • Sign up for article alerts and news from this journal
  • Contact us
  • Announcements

    C19 Rapid Review initiative

    Genome Medicine has joined the C19 Rapid Review initiative, a cross-publisher collaboration to ensure that COVID-19 research is reviewed and published as quickly and openly as possible. Learn more here

    Submissions from medRxiv 

    Authors are now able to submit manuscripts to Genome Medicine directly from medRxiv without having to re-upload files.

    Portable peer review

    To reduce time spent on serial submissions and iterative reviewing, Genome Medicine offers to consider manuscripts on the basis of reviews received at other journals. We also support transfers of reviews obtained at Genome Medicine to other journals, including those outside of BMC and Springer Nature. Learn more from our peer review policy page.

    COVID-19 submissions

    In response to the current SARS-CoV-2 pandemic Genome Medicine editors will treat relevant submissions with high priority.

Annual Journal Metrics